Iridex to Report Fourth Quarter and Full Year 2024 Financial Results on March 27, 2025
Iridex (NASDAQ: IRIX), a provider of laser-based medical systems for glaucoma and retinal diseases treatment, has scheduled its Fourth Quarter and Full Year 2024 financial results announcement for March 27, 2025, after market close.
The company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET on the same day. Investors can join via phone at +1-888-596-4144 (Conference ID: 5685253) or access the webcast through the Event Calendar on Iridex's investor relations website.
Iridex (NASDAQ: IRIX), fornitore di sistemi medici basati su laser per il trattamento del glaucoma e delle malattie retiniche, ha programmato l'annuncio dei risultati finanziari del Quarto Trimestre e dell'Intero Anno 2024 per il 27 marzo 2025, dopo la chiusura del mercato.
L'azienda ospiterà una conference call alle 14:00 PT / 17:00 ET nello stesso giorno. Gli investitori possono partecipare telefonicamente al numero +1-888-596-4144 (ID conferenza: 5685253) oppure accedere al webcast tramite il Calendario Eventi sul sito web delle relazioni con gli investitori di Iridex.
Iridex (NASDAQ: IRIX), proveedor de sistemas médicos basados en láser para el tratamiento del glaucoma y enfermedades retinianas, ha programado el anuncio de sus resultados financieros del Cuarto Trimestre y del Año Completo 2024 para el 27 de marzo de 2025, después del cierre del mercado.
La compañía llevará a cabo una conferencia telefónica a las 2:00 p.m. PT / 5:00 p.m. ET el mismo día. Los inversores pueden unirse por teléfono al +1-888-596-4144 (ID de conferencia: 5685253) o acceder al webcast a través del Calendario de Eventos en el sitio web de relaciones con inversores de Iridex.
Iridex (NASDAQ: IRIX)는 녹내장 및 망막 질환 치료를 위한 레이저 기반 의료 시스템 제공업체로서, 2024년 4분기 및 연간 재무 결과 발표를 2025년 3월 27일 시장 종료 후에 진행할 예정입니다.
회사는 같은 날 오후 2시 PT / 오후 5시 ET에 컨퍼런스 콜을 개최할 것입니다. 투자자들은 +1-888-596-4144(컨퍼런스 ID: 5685253)로 전화로 참여하거나 Iridex의 투자자 관계 웹사이트의 이벤트 캘린더를 통해 웹캐스트에 접속할 수 있습니다.
Iridex (NASDAQ: IRIX), fournisseur de systèmes médicaux basés sur le laser pour le traitement du glaucome et des maladies rétiniennes, a programmé l'annonce de ses résultats financiers du quatrième trimestre et de l'année complète 2024 pour le 27 mars 2025, après la fermeture du marché.
L'entreprise organisera une conférence téléphonique le même jour à 14h00 PT / 17h00 ET. Les investisseurs peuvent rejoindre par téléphone au +1-888-596-4144 (ID de conférence : 5685253) ou accéder au webinaire via le calendrier des événements sur le site des relations investisseurs d'Iridex.
Iridex (NASDAQ: IRIX), Anbieter von laserbasierten medizinischen Systemen zur Behandlung von Glaukom und Netzhauterkrankungen, hat die Bekanntgabe seiner Finanzergebnisse für das vierte Quartal und das Gesamtjahr 2024 für den 27. März 2025 nach Marktschluss angesetzt.
Das Unternehmen wird am selben Tag um 14:00 Uhr PT / 17:00 Uhr ET eine Telefonkonferenz abhalten. Investoren können sich telefonisch unter +1-888-596-4144 (Konferenz-ID: 5685253) einwählen oder über den Veranstaltungs-Kalender auf der Investor-Relations-Website von Iridex auf das Webcast zugreifen.
- None.
- None.
MOUNTAIN VIEW, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems and delivery devices for the treatment of glaucoma and retinal diseases, today announced the Company plans to release financial results for the fourth quarter and full year 2024 and provide a business update after the close of trading on Thursday, March 27, 2025.
The Company’s management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing +1-888-596-4144 and providing conference ID: 5685253. A live and recorded webcast on the “Event Calendar” page of the “Investors” section of the Company’s website at www.iridex.com.
About Iridex Corporation
Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com.
MicroPulse® is a registered trademark of Iridex Corporation, Inc. in the United States, Europe and other jurisdictions. © 2025 Iridex Corporation. All rights reserved.
Investor Relations Contact:
Philip Taylor
Gilmartin Group
investors@iridex.com
FAQ
When will Iridex (IRIX) release Q4 and FY 2024 earnings?
How can investors join Iridex's (IRIX) Q4 2024 earnings call?
What is Iridex's (IRIX) main business focus?
Where can I find Iridex's (IRIX) earnings webcast?
